Acta Scientific Microbiology (ISSN: 2581-3226)

Case Report Volume 5 Issue 7

Emergence of Delta Plus (AY.1) and Kappa (B.1.617.1) Variants of SARS-CoV-2 in Second Wave of India: A Case Series from Eastern Uttar Pradesh

Amresh Kumar Singh1, Sushil Kumar2*, Suraj Prasad2, Indra P Adhikari3, Vivek Gaur1, Ankur Kumar1, Rajkishore Singh4 and Ganesh Kumar5

1Department of Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India

2Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India

3Department of Biochemistry, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India

4Department of Medicine, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India

5Department of Radiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India

*Corresponding Author: Sushil Kumar, Assistant Professor, Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India.

Received: June 02, 2022; Published: June 27, 2022

Prognosis of a COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is determined by how the host and virus variant interact with each other. The second wave was spreading at a breakneck pace in India, eventually and became a "tsunami by spreading of delta (B.1.617.2) variant. To determine the cause of this condition, randomly chosen positive SARS-CoV-2 samples were sequenced for the detection of variants responsible for this miserable situation. We have found mainly delta variants in clinical samples. Surprisingly, first time two delta plus (AY.1) and one kappa (B.1.617.1) variants of SARS-CoV-2 were also reported on July 2, 2021 from our centre of Uttar Pradesh. Unfortunately, among these, two non-vaccinated cases, person infected with delta plus and another with kappa variants had loss of their life admitted in ICU COVID-19 ward with severe conditions. Remaining, one case infected with delta plus was recovered who had already taken the vaccination of both doses. This finding suggests that SARS-CoV-2 genome variations have a substantial influence on COVID-19 outcome, resulting in an increase in reproduction number (R0) in the second wave. However, our findings point to a possible role for vaccination against the more lethal double-mutated delta plus variant. This primary report also opens a door towards large-scale gene sequencing of SARS-CoV-2 samples in order to develop precautionary measures against subsequent waves.

Keywords:SARS-CoV-2; Delta Plus Variant; Kappa Variant; Sequencing; COVID-19

References

  1. Kumar SU., et al. “The rise and impact of COVID-19 in India”. Frontiers in Medicine (Lausanne) 7 (2020): 250.
  2. Singh AK., et al. “Association of different biomarkers and CT value of RT-PCR with mortality in COVID-19 cases attended at tertiary care centre in India”. International Journal of Biomedical and Advance Research12.6 (2021): e5610.
  3. info. worldometer (2021).
  4. Shahhosseini N., et al. "Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern". Microorganisms5 (2021): 926.
  5. Harvey WT., et al. “SARS-CoV-2 variants, spike mutations and immune escape”. Nature Reviews Microbiology 19 (2021): 409-424.
  6. “Tracking SARS-CoV-2 variants”. World Health Organization.
  7. “Delta Variant: What We Know About the Science”. Centers for Disease Control and Prevention.
  8. “SARS-CoV-2 Variant Classifications and Definitions". Centers for Disease Control and Prevention (2021).
  9. Singh AK., et al. “Assessment of Severity and Outcome of COVID-19 Cases by Haematological and Biochemical Markers at Tertiary Care Centre in India”. Journal of Advances in Medicine and Medical Research23 (2020): 196-207.
  10. “Guidance on Personal Protective Equipment (PPE) To Be Used By Healthcare Workers during Management of Patients with Confirmed Ebola or Persons under Investigation (PUIs) for Ebola who are Clinically Unstable or Have Bleeding, Vomiting, or Diarrhea in U.S. Hospitals, Including Procedures for Donning and Doffing PPE”. Centre for Disease Control and Prevention Atlanta USA (2021).
  11. Kumar P., et al. “Integrated genomic view of SARS-CoV-2 in India”. bioRxiv preprint. (2020).
  12. Elhabyan A., et al. “The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review”. Virus Research 289 (2020): 198163.
  13. Dhar D and Mohanty A. “Gut microbiota and Covid-19- possible link and implications”. Virus Research 285 (2020): 198018.
  14. “SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 17 (PDF) (Briefing)”. Public Health England (2021): GOV-8576. 
  15. Sharma M. "New 'Delta Plus' variant of SARS-CoV-2 identified; here's what we know so far". India Today (2021).
  16. Tang JW., et al. “Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK”. The Journal of Infection4 (2021): e8-e10.
  17. "India says new COVID variant is a concern". Reuters. Bengaluru. (2021).
  18. Biswas S. "Delta plus: Scientists say too early to tell risk of Covid-19 variant". BBC News (2021).
  19. “Weekly epidemiological update on COVID-19 27 April 2021”. World Health Organization (2021).
  20. Le Page M. "Indian covid-19 variant (B.1.617)". New Scientist (2021). 
  21. “SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 10”. Public Health England (2021): GOV-8226.
  22. Nuki P and Newey S. "Arrival of India's 'double mutation' adds to variant woes, but threat posed remains unclear". The Telegraph (2021).
  23. Mehta P., et al. “Severe Acute Respiratory Syndrome Coronavirus-2 genome sequence variations relate to morbidity and mortality in Coronavirus Disease-19”. bioRxiv24 (2021): 445374.

Citation

Citation: Sushil Kumar., et al. “Emergence of Delta Plus (AY.1) and Kappa (B.1.617.1) Variants of SARS-CoV-2 in Second Wave of India: A Case Series from Eastern Uttar Pradesh". Acta Scientific Microbiology 5.7 (2022): 95-101.

Copyright

Copyright: © 2022 Sushil Kumar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is August 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US